
isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m- nitrophenyl)-3,5–pyridinedicarboxylate
Absorption
Nimodipine is rapidly absorbed after oral administration. Bioavailability is 13% and Tmax is approximately 1 h. Food decreases peak plasma concentration 68% and bioavailability 38%.
Distribution
Nimodipine protein binding is over 95%.
Metabolism
Extensive first-pass metabolism in the liver.
Elimination
Nimodipine is eliminated in urine (less than 1% unchanged), and metabolites are considerably less active than parent compound. Terminal t1/2 is 8 to 9 h, and initial t1/2 is 1 to 2 h.
Special Populations
Elderly
AUC and C max were approximately 2–fold higher; this response is not considered important.
Hepatic Function Impairment
Nimodipine bioavailability is increased, C max almost doubles, and dosage adjustment is necessary in patients with hepatic cirrhosis.
Beta-blockers
May cause increased adverse reactions because of myocardial contractility or AV conduction depression.
Cimetidine, grapefruit juice
Nimodipine plasma levels may be elevated, increasing the pharmacologic effects and adverse reactions.
Fentanyl
May cause severe hypotension or increased fluid requirements.
Other hypertensive agents
May have additive effects.
預防、治療因動膜瘤引起之蜘蛛膜下出血後,腦血管痙攣所引起的缺血性神經缺損,可使用二星期,需附電腦斷層掃描(CT Scan)報告。




